"Sometimes, there is more than a single answer to a question; this certainly applies to patients with benign prostatic disease," writes Gopal H. Badlani, MD.

"With the requirements for an E/M code as noted above, we agree with you that the supporting documentation, if appropriately documented, would support a level 3 outpatient visit for a visit regarding ...

The app-based intervention led to a significant 8-point reduction in IPSS, indicating substantial improvement in LUTS. The app includes physiotherapy, lifestyle modifications, and educational modules, ...

A panelist discusses how benign prostatic hyperplasia (BPH) treatment has evolved to include a spectrum of minimally invasive and surgical interventions, ranging from emerging technologies like ...

“Given the rates in epidemiologic studies and surveys showing that up to 70% of women are symptomatic, we were surprised to find that only 9% [filled] a prescription,” says Ekene Enemchukwu, MD, MPH, ...

The SECuRE trial is assessing 67Cu-SAR-bisPSMA in mCRPC, focusing on pre-chemotherapy settings and combination therapy with enzalutamide. Interim data shows significant PSA reductions and disease ...

ImmunityBio seeks FDA approval for Anktiva plus BCG in BCG-unresponsive NMIBC papillary indication, supported by QUILT-3.032 trial data. The QUILT-3.032 trial showed a 55.4% disease-free survival at ...

“I think it will help patients decide what prostate surgery they want,” says Naeem Bhojani, MD, FRCSC. Three-month data from the WATER III trial (NCT04801381) were recently shared during the 40th ...

Sima P. Porten, MD, MPH, discusses the need to better understand how genetic makeup influences how individuals process environmental toxins. Firefighters face an increased risk of bladder cancer ...

The study utilized 68Ga-PSMA-11 PET imaging to assess outcomes in prostate cancer patients treated with 177Lu-PSMA-617, focusing on whole-body SUVmean as a key parameter. Higher whole-body SUVmean ...

“It definitely makes it easier for providers [to counsel patients]," says Landon Trost, MD. With the FDA’s recent class-wide labeling changes for testosterone products 1, urologist Landon Trost, MD, ...

“We go into medicine to take care of people and to help them, and when that doesn't transpire, it's a very tough reality,” says Aditya Bagrodia, MD, FACS.